• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强超声能区分肝内胆管细胞癌和肝细胞癌吗?

Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?

机构信息

Department of Medical Ultrasound, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.

Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.

出版信息

World J Gastroenterol. 2020 Jul 21;26(27):3938-3951. doi: 10.3748/wjg.v26.i27.3938.

DOI:10.3748/wjg.v26.i27.3938
PMID:32774068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7385563/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) differ in treatment and prognosis, warranting an effective differential diagnosis between them. The LR-M category in the contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) was set up for lesions that are malignant but not specific to HCC. However, a substantial number of HCC cases in this category elevated the diagnostic challenge.

AIM

To investigate the possibility and efficacy of differentiating ICC from HCC classified in the LR-M category according to the CEUS LI-RADS.

METHODS

Patients with complete CEUS records together with pathologically confirmed ICC and LR-M HCC (HCC classified in the CEUS LI-RADS LR-M category) between January 2015 and October 2018 were included in this retrospective study. Each ICC was assigned a category as per the CEUS LI-RADS. The enhancement pattern, washout timing, and washout degree between the ICC and LR-M HCC were compared using the test. Logistic regression analysis was used for prediction of ICC. Receiver operating characteristic (ROC) curve analysis was used to investigate the possibility of LR-M criteria and serum tumor markers in differentiating ICC from LR-M HCC.

RESULTS

A total of 228 nodules (99 ICCs and 129 LR-M HCCs) in 228 patients were included. The mean sizes of ICC and LR-M HCC were 6.3 ± 2.8 cm and 5.5 ± 3.5 cm, respectively ( = 0.03). Peripheral rim-like arterial phase hyperenhancement (APHE) was detected in 50.5% (50/99) of ICCs 16.3% (21/129) of LR-M HCCs ( < 0.001). Early washout was found in 93.4% (93/99) of ICCs 96.1% (124/129) of LR-M HCCs ( > 0.05). Marked washout was observed in 23.2% (23/99) of ICCs and 7.8% (10/129) of LR-M HCCs = 0.002), while this feature did not show up alone either in ICC or LR-M HCC. Homogeneous hyperenhancement was detected in 15.2% (15/99) of ICCs and 37.2% (48/129) of LR-M HCCs ( < 0.001). The logistic regression showed that rim APHE, carbohydrate antigen 19-9 (CA 19-9), and alpha fetoprotein (AFP) had significant correlations with ICC ( = 1.251, 3.074, and -2.767, respectively; < 0.01). Rim APHE presented the best enhancement pattern for diagnosing ICC, with an area under the ROC curve (AUC) of 0.70, sensitivity of 70.4%, and specificity of 68.8%. When rim hyperenhancement was coupled with elevated CA 19-9 and normal AFP, the AUC and sensitivity improved to 0.82 and 100%, respectively, with specificity decreasing to 63.9%.

CONCLUSION

Rim APHE is a key predictor for differentiating ICC from LR-M HCC. Rim APHE plus elevated CA 19-9 and normal AFP is a strong predictor of ICC rather than LR-M HCC. Early washout and marked washout have limited value for the differentiation between the two entities.

摘要

背景

肝细胞癌(HCC)和肝内胆管细胞癌(ICC)在治疗和预后方面存在差异,因此需要对它们进行有效的鉴别诊断。对比增强超声(CEUS)肝脏影像报告和数据系统(LI-RADS)中的 LR-M 类别是为了区分那些恶性但不特异于 HCC 的病变而设立的。然而,这一类别中的相当一部分 HCC 病例增加了诊断的挑战。

目的

探讨根据 CEUS LI-RADS 鉴别 ICC 和 LR-M HCC 的可能性和效果。

方法

回顾性分析 2015 年 1 月至 2018 年 10 月期间具有完整 CEUS 记录并经病理证实的 ICC 和 LR-M HCC(CEUS LI-RADS LR-M 类别中的 HCC)患者。根据 CEUS LI-RADS 对每个 ICC 进行分类。采用 检验比较 ICC 和 LR-M HCC 的增强模式、洗脱时间和洗脱程度。采用 logistic 回归分析预测 ICC。采用受试者工作特征(ROC)曲线分析探讨 LR-M 标准和血清肿瘤标志物在鉴别 ICC 与 LR-M HCC 中的可能性。

结果

共纳入 228 例患者的 228 个结节(99 个 ICC 和 129 个 LR-M HCC)。ICC 和 LR-M HCC 的平均大小分别为 6.3±2.8cm 和 5.5±3.5cm( = 0.03)。50.5%(50/99)的 ICC 和 16.3%(21/129)的 LR-M HCC 出现边缘状动脉期高增强(APHE)( < 0.001)。93.4%(93/99)的 ICC 和 96.1%(124/129)的 LR-M HCC 出现早期洗脱( > 0.05)。23.2%(23/99)的 ICC 和 7.8%(10/129)的 LR-M HCC 出现明显洗脱( = 0.002),而这一特征在 ICC 或 LR-M HCC 中均未单独出现。15.2%(15/99)的 ICC 和 37.2%(48/129)的 LR-M HCC 出现均匀高增强( < 0.001)。logistic 回归显示,边缘 APHE、糖抗原 19-9(CA 19-9)和甲胎蛋白(AFP)与 ICC 有显著相关性( = 1.251、3.074 和-2.767,均 < 0.01)。边缘 APHE 对诊断 ICC 的增强模式最佳,ROC 曲线下面积(AUC)为 0.70,灵敏度为 70.4%,特异性为 68.8%。当边缘高增强与 CA 19-9 升高和 AFP 正常结合时,AUC 和灵敏度分别提高至 0.82 和 100%,特异性降至 63.9%。

结论

边缘 APHE 是鉴别 ICC 和 LR-M HCC 的关键预测指标。边缘 APHE 加上 CA 19-9 升高和 AFP 正常是鉴别 ICC 而不是 LR-M HCC 的有力预测指标。早期洗脱和明显洗脱对两者的鉴别价值有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/0209f0f9042e/WJG-26-3938-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/7f1d198b3e9a/WJG-26-3938-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/cd493188d17b/WJG-26-3938-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/6828acccb1d5/WJG-26-3938-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/23c5a0f1a6f1/WJG-26-3938-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/0209f0f9042e/WJG-26-3938-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/7f1d198b3e9a/WJG-26-3938-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/cd493188d17b/WJG-26-3938-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/6828acccb1d5/WJG-26-3938-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/23c5a0f1a6f1/WJG-26-3938-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/710a/7385563/0209f0f9042e/WJG-26-3938-g005.jpg

相似文献

1
Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?增强超声能区分肝内胆管细胞癌和肝细胞癌吗?
World J Gastroenterol. 2020 Jul 21;26(27):3938-3951. doi: 10.3748/wjg.v26.i27.3938.
2
Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.在有和无风险因素的患者中鉴别肝内胆管细胞癌和肝细胞癌:对比增强超声肝脏成像报告和数据系统 2017 版 LR-M 标准的评估。
Eur Radiol. 2020 Jan;30(1):461-470. doi: 10.1007/s00330-019-06317-2. Epub 2019 Jul 11.
3
A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.基于改良对比增强超声 LI-RADS M 标准的多参数肝内胆管细胞癌评分系统,用于鉴别肝内胆管细胞癌与肝细胞癌。
Abdom Radiol (NY). 2024 Feb;49(2):458-470. doi: 10.1007/s00261-023-04114-6. Epub 2024 Jan 16.
4
Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.超声造影联合血清生物标志物鉴别肝细胞胆管癌与肝细胞癌及肝内胆管癌
World J Gastroenterol. 2020 Dec 14;26(46):7325-7337. doi: 10.3748/wjg.v26.i46.7325.
5
Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.超声造影肝脏影像报告与数据系统:在肝细胞癌和胆管细胞癌诊断中的优缺点。
World J Gastroenterol. 2022 Jul 21;28(27):3488-3502. doi: 10.3748/wjg.v28.i27.3488.
6
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.在一项多中心回顾性研究中,1006 个结节的对比超声 LI-RADS LR-5 可识别肝硬化中的肝细胞癌。
J Hepatol. 2018 Mar;68(3):485-492. doi: 10.1016/j.jhep.2017.11.007. Epub 2017 Nov 11.
7
Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.对比增强超声在低分化肝细胞癌与肝内胆管癌鉴别诊断中的应用
J Ultrasound Med. 2022 May;41(5):1213-1225. doi: 10.1002/jum.15812. Epub 2021 Aug 23.
8
LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.肝脏影像报告和数据系统-超声造影 - 关于高危人群肝细胞癌诊断的超声造影算法提案
Ultraschall Med. 2016 Dec;37(6):627-634. doi: 10.1055/s-0042-112221. Epub 2016 Aug 3.
9
Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.高危患者肝内胆管细胞癌与肝细胞癌的鉴别诊断:应用超声造影的预测模型。
World J Gastroenterol. 2018 Sep 7;24(33):3786-3798. doi: 10.3748/wjg.v24.i33.3786.
10
Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.超声造影对肝细胞癌鉴别诊断的诊断准确性:爱克发与CEUS-LI-RADS对比
Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1036-1044. doi: 10.1097/MEG.0000000000000916.

引用本文的文献

1
Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma.超声造影诊断肝内胆管癌亚型:与低分化肝细胞癌的对比研究
Cancer Imaging. 2025 Aug 27;25(1):107. doi: 10.1186/s40644-025-00923-8.
2
Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma.基于超声造影的联合影像组学和临床模型用于术前预测CK19阳性肝细胞癌的开发与验证
Abdom Radiol (NY). 2025 Feb 5. doi: 10.1007/s00261-025-04799-x.
3

本文引用的文献

1
Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.CEUS LI-RADS 在肝癌风险患者中对 20mm 或更小的肝脏结节的特征诊断准确性。
Radiology. 2020 Feb;294(2):329-339. doi: 10.1148/radiol.2019191086. Epub 2019 Dec 3.
2
Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection.对比增强超声 LI-RADS 版本 2017 评估:在乙型肝炎感染患者的 2020 个肝脏结节中的应用。
Radiology. 2020 Feb;294(2):299-307. doi: 10.1148/radiol.2019190878. Epub 2019 Nov 26.
3
Feasibility of large language models for CEUS LI-RADS categorization of small liver nodules in patients at risk for hepatocellular carcinoma.
大语言模型用于肝细胞癌高危患者小肝结节的CEUS LI-RADS分类的可行性
Front Oncol. 2024 Dec 18;14:1513608. doi: 10.3389/fonc.2024.1513608. eCollection 2024.
4
Machine learning model based on dynamic contrast-enhanced ultrasound assisting LI-RADS diagnosis of HCC: A multicenter diagnostic study.基于动态对比增强超声的机器学习模型辅助肝脏影像报告和数据系统(LI-RADS)诊断肝细胞癌:一项多中心诊断研究
Heliyon. 2024 Oct 2;10(20):e38850. doi: 10.1016/j.heliyon.2024.e38850. eCollection 2024 Oct 30.
5
Rare infiltrative primary hepatic angiosarcoma: A case report and review of literature.罕见的浸润性原发性肝血管肉瘤:一例报告并文献复习
World J Gastrointest Oncol. 2024 Jul 15;16(7):3341-3349. doi: 10.4251/wjgo.v16.i7.3341.
6
A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.基于改良对比增强超声 LI-RADS M 标准的多参数肝内胆管细胞癌评分系统,用于鉴别肝内胆管细胞癌与肝细胞癌。
Abdom Radiol (NY). 2024 Feb;49(2):458-470. doi: 10.1007/s00261-023-04114-6. Epub 2024 Jan 16.
7
A nomogram based on ultrasonographic features and clinical indicators for differentiating mass-forming intrahepatic cholangiocarcinoma and liver metastatic colorectal adenocarcinoma.基于超声特征和临床指标的列线图用于鉴别肿块型肝内胆管癌和肝转移性结直肠腺癌
Front Oncol. 2023 Oct 31;13:1245686. doi: 10.3389/fonc.2023.1245686. eCollection 2023.
8
Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.磁共振成像和超声造影对鉴别肝内胆管细胞癌与肝细胞癌的诊断性能:荟萃分析。
Abdom Radiol (NY). 2024 Jan;49(1):34-48. doi: 10.1007/s00261-023-04064-z. Epub 2023 Oct 12.
9
A model incorporating clinicopathologic and liver imaging reporting and data system-based magnetic resonance imaging features to identify hepatocellular carcinoma in LR-M observations.纳入临床病理和肝脏影像报告和数据系统(LI-RADS)基于磁共振成像特征的模型,以识别 LR-M 观察中的肝细胞癌。
Diagn Interv Radiol. 2023 Nov 7;29(6):741-752. doi: 10.4274/dir.2023.232215. Epub 2023 Sep 4.
10
Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives.对比增强成像在肝内胆管癌管理中的应用:现状与未来展望
Cancers (Basel). 2023 Jun 28;15(13):3393. doi: 10.3390/cancers15133393.
Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.
在有和无风险因素的患者中鉴别肝内胆管细胞癌和肝细胞癌:对比增强超声肝脏成像报告和数据系统 2017 版 LR-M 标准的评估。
Eur Radiol. 2020 Jan;30(1):461-470. doi: 10.1007/s00330-019-06317-2. Epub 2019 Jul 11.
4
Enhancement Patterns of Intrahepatic Cholangiocarcinoma on Contrast-Enhanced Ultrasound: Correlation with Clinicopathologic Findings and Prognosis.肝内胆管癌在超声造影上的增强模式:与临床病理特征及预后的相关性
Ultrasound Med Biol. 2019 Jan;45(1):26-34. doi: 10.1016/j.ultrasmedbio.2018.08.014. Epub 2018 Oct 3.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.高危患者肝内胆管细胞癌与肝细胞癌的鉴别诊断:应用超声造影的预测模型。
World J Gastroenterol. 2018 Sep 7;24(33):3786-3798. doi: 10.3748/wjg.v24.i33.3786.
7
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.在一项多中心回顾性研究中,1006 个结节的对比超声 LI-RADS LR-5 可识别肝硬化中的肝细胞癌。
J Hepatol. 2018 Mar;68(3):485-492. doi: 10.1016/j.jhep.2017.11.007. Epub 2017 Nov 11.
8
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.肝细胞癌和肝内胆管癌的流行病学
Cancer Control. 2017 Jul-Sep;24(3):1073274817729245. doi: 10.1177/1073274817729245.
9
Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system.对比增强超声(CEUS)肝脏影像报告和数据系统(LI-RADS)2017 - 与 CT/MRI 系统相比的重要差异综述。
Clin Mol Hepatol. 2017 Dec;23(4):280-289. doi: 10.3350/cmh.2017.0037. Epub 2017 Sep 15.
10
CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI.CEUS LI-RADS:算法、实施及与 CT/MRI 的主要差异。
Abdom Radiol (NY). 2018 Jan;43(1):127-142. doi: 10.1007/s00261-017-1250-0.